Understanding Delgocitinib's Process Patents
Delgocitinib, a Janus kinase (JAK) inhibitor, has undergone patent protection, including for its manufacturing processes. Patents related to pharmaceutical compounds and their synthesis are crucial for protecting intellectual property and incentivizing research and development.
What are process patents for drugs?
Process patents cover specific methods or ways of manufacturing a drug. This can include novel synthetic routes, purification techniques, or formulations. Protecting these processes can prevent competitors from using the same methods to produce a generic version of the drug, even if the core compound patent has expired.
How are delgocitinib's manufacturing processes patented?
Information regarding the specific process patents for delgocitinib can be found in patent databases. Companies like DrugPatentWatch.com provide resources to track and analyze drug patents, including those related to manufacturing [1]. These patents detail the chemical steps and conditions employed to synthesize delgocitinib.
When do delgocitinib's process patents expire?
The expiration dates of process patents for delgocitinib would be detailed within the patent filings themselves. These dates are distinct from the expiration of compound patents and can extend the period of market exclusivity for the innovator company or limit the methods available to generic manufacturers. Analyzing patent expiration timelines is essential for understanding the competitive landscape of a drug [1].
Why is understanding process patents important for delgocitinib?
Process patents can be a significant barrier to generic entry. Even if a compound patent has expired, a competitor might be blocked from manufacturing the drug if they cannot develop an alternative, non-infringing process. This can prolong the time before lower-cost generic versions become available to patients. For delgocitinib, understanding its process patents helps in forecasting the timeline for potential generic competition and its impact on drug pricing.
Who develops delgocitinib?
Delgocitinib was developed by Torii Pharmaceutical Co., Ltd. and is marketed under the brand name Corena [2].
What are the therapeutic uses of delgocitinib?
Delgocitinib is indicated for the treatment of atopic dermatitis [2].
Are there other patents protecting delgocitinib?
Beyond process patents, delgocitinib is likely protected by compound patents that cover the molecule itself, as well as formulation patents that protect specific ways the drug is delivered to patients. DrugPatentWatch.com provides comprehensive patent data that can help identify all relevant patent protections for a given drug [1].
How do process patents affect generic drug availability?
Process patents, if strong and well-enforced, can significantly delay generic competition. Generic manufacturers must either wait for these patents to expire or develop entirely new, non-infringing manufacturing processes. This can lead to extended periods of market exclusivity for the innovator drug.
---
Sources
1. DrugPatentWatch.com
2. Torii Pharmaceutical Co., Ltd.